• Something wrong with this record ?

Multidrug Resistance-Associated Protein 2 Deficiency Aggravates Estrogen-Induced Impairment of Bile Acid Metabolomics in Rats

F. Alaei Faradonbeh, H. Lastuvkova, J. Cermanova, M. Hroch, Z. Nova, M. Uher, P. Hirsova, P. Pavek, S. Micuda

. 2022 ; 13 (-) : 859294. [pub] 20220321

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22017547

Grant support
R01 DK130884 NIDDK NIH HHS - United States

Multidrug resistance-associated protein 2 (Mrp2) mediates biliary secretion of anionic endobiotics and xenobiotics. Genetic alteration of Mrp2 leads to conjugated hyperbilirubinemia and predisposes to the development of intrahepatic cholestasis of pregnancy (ICP), characterized by increased plasma bile acids (BAs) due to mechanisms that are incompletely understood. Therefore, this study aimed to characterize BA metabolomics during experimental Mrp2 deficiency and ICP. ICP was modeled by ethinylestradiol (EE) administration to Mrp2-deficient (TR) rats and their wild-type (WT) controls. Spectra of BAs were analyzed in plasma, bile, and stool using an advanced liquid chromatography-mass spectrometry (LC-MS) method. Changes in BA-related genes and proteins were analyzed in the liver and intestine. Vehicle-administered TR rats demonstrated higher plasma BA concentrations consistent with reduced BA biliary secretion and increased BA efflux from hepatocytes to blood via upregulated multidrug resistance-associated protein 3 (Mrp3) and multidrug resistance-associated protein 4 (Mrp4) transporters. TR rats also showed a decrease in intestinal BA reabsorption due to reduced ileal sodium/bile acid cotransporter (Asbt) expression. Analysis of regulatory mechanisms indicated that activation of the hepatic constitutive androstane receptor (CAR)-Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway by accumulating bilirubin may be responsible for changes in BA metabolomics in TR rats. Ethinylestradiol administration to TR rats further increased plasma BA concentrations as a result of reduced BA uptake and increased efflux via reduced Slco1a1 and upregulated Mrp4 transporters. These results demonstrate that Mrp2-deficient organism is more sensitive to estrogen-induced cholestasis. Inherited deficiency in Mrp2 is associated with activation of Mrp3 and Mrp4 proteins, which is further accentuated by increased estrogen. Bile acid monitoring is therefore highly desirable in pregnant women with conjugated hyperbilirubinemia for early detection of intrahepatic cholestasis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017547
003      
CZ-PrNML
005      
20220720100256.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphys.2022.859294 $2 doi
035    __
$a (PubMed)35388287
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Alaei Faradonbeh, Fatemeh $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
245    10
$a Multidrug Resistance-Associated Protein 2 Deficiency Aggravates Estrogen-Induced Impairment of Bile Acid Metabolomics in Rats / $c F. Alaei Faradonbeh, H. Lastuvkova, J. Cermanova, M. Hroch, Z. Nova, M. Uher, P. Hirsova, P. Pavek, S. Micuda
520    9_
$a Multidrug resistance-associated protein 2 (Mrp2) mediates biliary secretion of anionic endobiotics and xenobiotics. Genetic alteration of Mrp2 leads to conjugated hyperbilirubinemia and predisposes to the development of intrahepatic cholestasis of pregnancy (ICP), characterized by increased plasma bile acids (BAs) due to mechanisms that are incompletely understood. Therefore, this study aimed to characterize BA metabolomics during experimental Mrp2 deficiency and ICP. ICP was modeled by ethinylestradiol (EE) administration to Mrp2-deficient (TR) rats and their wild-type (WT) controls. Spectra of BAs were analyzed in plasma, bile, and stool using an advanced liquid chromatography-mass spectrometry (LC-MS) method. Changes in BA-related genes and proteins were analyzed in the liver and intestine. Vehicle-administered TR rats demonstrated higher plasma BA concentrations consistent with reduced BA biliary secretion and increased BA efflux from hepatocytes to blood via upregulated multidrug resistance-associated protein 3 (Mrp3) and multidrug resistance-associated protein 4 (Mrp4) transporters. TR rats also showed a decrease in intestinal BA reabsorption due to reduced ileal sodium/bile acid cotransporter (Asbt) expression. Analysis of regulatory mechanisms indicated that activation of the hepatic constitutive androstane receptor (CAR)-Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway by accumulating bilirubin may be responsible for changes in BA metabolomics in TR rats. Ethinylestradiol administration to TR rats further increased plasma BA concentrations as a result of reduced BA uptake and increased efflux via reduced Slco1a1 and upregulated Mrp4 transporters. These results demonstrate that Mrp2-deficient organism is more sensitive to estrogen-induced cholestasis. Inherited deficiency in Mrp2 is associated with activation of Mrp3 and Mrp4 proteins, which is further accentuated by increased estrogen. Bile acid monitoring is therefore highly desirable in pregnant women with conjugated hyperbilirubinemia for early detection of intrahepatic cholestasis.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lastuvkova, Hana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Cermanova, Jolana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Hroch, Milos $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Nova, Zuzana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Uher, Martin $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Hirsova, Petra $u Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States
700    1_
$a Pavek, Petr $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czechia
700    1_
$a Micuda, Stanislav $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czechia
773    0_
$w MED00174601 $t Frontiers in physiology $x 1664-042X $g Roč. 13, č. - (2022), s. 859294
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35388287 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100251 $b ABA008
999    __
$a ind $b bmc $g 1816643 $s 1168789
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c - $d 859294 $e 20220321 $i 1664-042X $m Frontiers in physiology $n Front. physiol. $x MED00174601
GRA    __
$a R01 DK130884 $p NIDDK NIH HHS $2 United States
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Archiving options